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Original Article
Abstract
Purpose: Methotrexate (MTX) is an antimetabolite that is routinely used in thetreatment of hematological malignancies and during its metabolism leads tohyperhomocysteinemia that is associated with neurotoxicity. The purpose of thisprospective study is to determine whether the increase in plasma homocysteine(Hcy) concentration is related to MTX-induced neurotoxicity. Methods: Weinvestigated these changes for both newly diagnosed acute lymphoblastic leukemia(ALL) and lymphoblastic lymphoma (LL) pediatric patients treated at the NationalCancer Institute, Egypt. They were treated according to St. Jude total XV protocol toreceive 2.5 or 5 g/m2 MTX as a phase of consolidation and were selected betweenOctober 2009 and January 2010. Results: Twenty-nine patients were analyzed,M/F: 20/9, the mean age was 8 +/- 4.4 years. Hcy level above 15 µmol/L wasconsidered positive. Hcy levels mean at diagnosis, pre 1st HD MTX, post 1st HDMTX,Pre 2nd HDMTX, Post 2nd HDMTX were 12.10 µmol/L ± 4.17, 6.90 µmol/L ± 3.02,17.59 µmol/L ± 6.00, 7.21 µmol/L ± 2.73 and 13.74 µmol/L ± 4.75 respectively.Seventeen patients (58%) had features suggestive of neurotoxicity. Positive Hcylevels were associated with neurotoxicity p = 0.05, higher HDMTX 5 g/m2 P= 0.023.A highly significant relation was found between initial Hcy level at diagnosis andfinal Hcy level p = 0.001; the same as between Hcy level Post 1st HDMTX and thatPost 2nd HDMTX with p = 0.006. Conclusion: plasma Hcy concentration wassignificantly elevated after HDMTX administration and this elevation is associatedwith the observed neurotoxicity. Whether the elevation in Hcy concentration canprove an informative biomarker for neurotoxicity requires additional testing withother MTX regimens.
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1. IntroductionMethotrexate (MTX) is a folic acid antagonist used sincemany years in the treatment of hematologicalmalignancies. Its high dose (HD MTX) was prompted forthe hematological, central nervous system (CNS) andtesticular prophylaxis.1-6MTX is an inhibitor of dihydrofolate reductase (DHFR)resulting in a cellular depletion of tetrahydrofolates
(THF) that are normally essential for the conversion ofHomocysteine (Hcy) to methionine. This results intohyperhomocysteinemia7-10 that is associated withneurotoxicity11 and has been reported for years in themedical literature to present in acute, sub- acute orchronic syndromes12, 13. It may be transient andreversible but severe neurological disorders leading tocoma or even death may occur as well.14- 21
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In this study, assessment of the changes in Hcyconcentration in plasma was done for newly diagnosedacute lymphoblastic leukemia (ALL) and lymphoblasticlymphoma (LL) pediatric patients treated with HDMTX.The purpose of the study is to determine whether theincrease in plasma Hcy concentration is related toMTX-induced neurotoxicity.
2. Methods and MaterialsPediatric patients newly diagnosed as ALL ornon-Hodgkin’s LL, treated at the National CancerInstitute, Cairo University, Egypt were the subject of thisprospective study. They were treated according to St.Jude total XV protocol to receive > 1 g/m2 MTXaccording to hematological and CNS initial status anddisease stratification.22 They were selected between 1stof October 2009 and end of January 2010 to assess thecorrelation between the Hcy level and MTX inducedneurotoxicity. The local institute ethical committeeapproved the study and an informed consent was
obtained from the patients guardians prior to theirinclusion in the study.
2.1 Consolidation treatmentAfter the patient has achieved remission inductionfollowing a 6-week chemotherapeutic treatmentincluding triple intrathecal therapy22, consolidationconsisted of HDMTX given every 2 weeks. The HD MTX(5 g/m2 or 2.5 g/m2 over 24 hours whetherstandard/high- SR/HR- or low-risk -LR- armsrespectively), was given the 1st day in association withthe same triple intrathecal therapy including aracytine(Arac), hydrocortisone (HC) and MTX (Table 1). Folinicacid rescue was given intravenously at a dose of 15mg/m2 for standard/high-risk patients or 10 mg/m2 forlow-risk patient. It started 42 hours later and was givenevery 6 hours with modifications according to a specificschedule.22 Oral 6-mercaptopurine (6MP), 50 mg / m2/day was associated for 8 weeks to all risk groups.
Table 1: Details of consolidation phase of the protocol.Agent, dosage, and routes of administration Schedule day of consolidationHDMTX 5 g/m2 for SR or HR patients,2.5 g/m2 for LR patients administered 24 hours IVI D1,15,29 and 436-Mercapto Purine 50 mg/m2/day PO D1 to 56TIT age dependent: MTX 8, 10, 12 mg, HC 16, 20, 24 mg, Arac24, 30, 36 mg for ages 1 to 1.99, 2 to 2.99, and ≥ 3 year oldrespectively D1,15, 29, 43Arac: Aracytine; D: Day; HDMTX: High Dose Methotrexate; HR: High risk; HC: Hydrocortisone; IVI: IntraVenous Infusion;LR: Low Risk; MTX: Methotrexate; PO: Per Oral; SR: Standard Risk; TIT: Triple intrathecal.For HDMTX, one tenth of the total HDMTX loading dosewas given over one hour infusion and the remainingnine tenth of the dose were given via continuousinfusion over 23 hours. Before HDMTX administration,IV prehydration crystalloid infusion (at 100 ml/m2/hourfor low risk and 125 ml/m2/hour for standard/highrisk) with sodium bicarbonate given over 12 hours.Patients started HD MTX if urine PH was≥ 6.5.23Folinic acid rescue was given at hour 42 from the start ofHDMTX administration. The low dose group received 10mg/m2 of leucovorin every 6 hours for 5 doses, while thestandard and high risk groups received 15 mg/m2 every6 hours for 5 doses. The folinic acid dose was adjusted ifthe methotrexate plasma concentration was ≥ 1 µM athour 42 or ≥ 0.1 µM at hour 68.23
2.2 Homocysteine assayHcy measures were timed at diagnosis and relative tothe HDMTX treatment (Figure 1). Blood (3 to 4 mL) wascollected in EDTA tubes at diagnosis, immediately before1st and 2nd high dose MTX and 42 hours after each ofthem but before leucovorin treatment. The sampleswere stored at -20°C till time of analysis. Homocysteinewas estimated using the Hcy enzyme immunoassay
(EIA) kit (Axis-shield, UK) according to the methoddescribed by Frantzen et al. 1998.24
Figure 1: Timing of homocysteine level evaluation.Any increase in Hcy level above 15 µmol/L following atleast one of the two HDMTX, the final Hcy value wasconsidered positive. However, normal levels (5 – 15µmol/L) were considered negative when Hcy level afterboth 1st and 2nd HDMTX were negative.
2.3 Clinical neurotoxicityNeurotoxicity was evaluated from the results of clinicalneurological examination. This was carried out initiallyat diagnosis and every other week coinciding withHDMTX during the consolidation phase. The target wasto elicit any abnormal cognitive, motor or sensoryfindings. Moreover to detect any increase in intracranialtension in the form of headache, vomiting, blurring of
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vision or signs of meningeal irritation and finally to findout any cranial nerve affection. These were assessedusing a form based on common terminology criteria foradverse events version 4.0 CTCAE, national institutes ofhealth, national cancer institute.25Neurotoxicity was evaluated to be positive and given ascore I when was present within one day ofmethotrexate infusion and included one of the following:severe intractable vomiting > thrice not gastro intestinaltract (GIT) induced, headache, low activity, speechimpairment, memory impairment, disturbed level ofconsciousness, convulsions, syncopal attack (notcardiovascular induced) and coma. In its absence theclinical score was zero.
2.4 Radiological neurotoxicityRadiological neurotoxicity was evaluated from theresults of brain magnetic resonance imaging (MRI)findings. A base line brain MRI was initially carried outat diagnosis and subsequently at the end ofconsolidation phase 2 weeks after the last HD MTX andintrathecal therapy. All cases were examined by using1.5 Tesla superconducting MR imager (magnotomESPREE 1.5 T, Erlangen, Siemens, Germany).After intravenous administration of Gadolonium –DTPA0.3 mg/kg contrasted enhanced T1W1 in axial, sagittaland coronal places were obtained.Radiological methotrexate toxicity was to be consideredpositive and given a score I at the presence of one ormore of the following: demyelination, necrotizinglesions, mineralizing microangiopathy, vascularcomplications, cerebral infarcts, leukencephalopathy,white matter lesions or atrophy. In its absence the scorewas zero.If both clinical and radiological examination were ofscore zero, the MTX neurotoxicity net result wasconsidered negative and given a grade of I. If at least oneof both was score I, MTX neurotoxicity net result wasconsidered positive and given a grade of II. If both wereof score I, the MTX neurotoxicity net result wasconsidered positive and given a grade of III.
2.5 Statistical methodsData was analyzed using SPSS win statistical packageversion 20 (SPSS Inc., Chicago, IL). Numerical data wereexpressed as mean and standard deviation. Comparisonsbetween means where carried out using one-wayanalysis of variance (ANOVA) test followed by Dunnetttest for multiple comparisons.Qualitative data were expressed as frequency andpercentage. Chi-square test (Fisher’s exact test) wasused to examine the relation between qualitativevariables. For quantitative data, comparison between
two groups was done using either student t-test orMann-Whitney test (non-parametric t-test) asappropriate. Values of pre and post assessments wereanalyzed by paired t-test or wilcoxon signed rank test.
P-value ≤ 0.05 was considered significant.
3. ResultsOut of 40 cases, 29 cases were newly diagnosed ALL orLL. Of them, 20 were males and 9 were females. Theirage ranged from 2 to 17 with a mean of 8 ± 4.4 years.Eleven patients were excluded from analysis as they didnot complete the study. The patient’s characteristics areshown in Table 2 and 3.
3.1 Plasma Hcy concentrations at different check
pointsRegarding the final Hcy value, 18 cases (62%) were withpositive (above 15 µmol/L) values corresponding toincrease Hcy levels after at least one of the two HDMTXcycles.In this study the results of Hcy mean levels at diagnosis,pre first HD MTX, post first HDMTX, Pre second HDMTX,Post second HDMTX were 12.10 µmol/L ± 4.17, 6.90µmol/L ± 3.02, 17.59 µmol/L ± 6.00, 7.21 µmol/L ± 2.73and 13.74 µmol/L ± 4.75 respectively as shown in(Figure 2).
Table 2: Patients demographic and clinical characteristics.Patient characteristics No. (%)Total number of patients 29 100GenderMale 20 69Female 9 31Age (years)≤10 20 69>10 9 31DiagnosisALL SR 18 62ALL LR 9 31NHL 2 7MTX dose, mg/m22500 9 315000 20 69Immunophenotype (Lineage)B-cell 21 72.4T-cell 8 27.6Risk group (Arm)SR (ALL+NHLL) 20 69LR 9 31CNS StatusCNS 1 21 72.4CNS 2 6 20.7CNS 3 2 6.9
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Table 3: Patients with clinical and radiological neurological assessment.UPN Diagnosis MTX doseg/m2 Age CNS C. N.score R. N.score NNRgrade Blood sample Hcy in µmol/LInitial 1st MTX HD 2nd MTX HDPre Post Pre Post1 ALL SR 5 10 I 1 0 II 12.5 10.5 21 9.5 172 NHL Tcell 5 15 I 1 0 II 12 11 22 10.5 193 NHL LL B 5 3 I 1 0 II 23,14 6 19 6.5 12.54 ALL LR 2.5 4 I 1 0 II 12.5 8 21.5 9 155 ALL LR 2.5 3 II 1 0 II 7.5 5 9.5 6.5 8.56 ALL SR 5 14 II 1 0 II 8 5 11 4 7.57 ALL LR 2.5 3 II 1 0 II 8.5 6 16.5 7 118 ALL SR 5 5 I 1 0 II 10 6 14.5 8.5 139 ALL Tcell 5 10 I 1 0 II 12.5 11 24 11 1710 ALL Tcell 5 13 I 1 0 II 12.5 8 20 8.5 1611 ALL SR 5 17 I 1 0 II 14 12 34.5,36 11 2212 ALL LR 2.5 5 I 1 0 II 22,22 7 14 7.5 20,2513 ALL SR 5 9 I 1 1 III 14 12 24 12.5 1814 ALL SR 5 11 II 1 1 III 12.5 5.5 14.5 6.5 1515 ALL SR 5 5 I 0 1 II 11 3.5 19 4 1016 ALL Tcell 5 11 II 0 1 II 9 4 12.5 6.5 1317 ALL Tcell 5 4 III 0 1 II 12 6 16 7 12.518 ALL Tcell 5 5 I 0 0 I 8 3.5 12.5 6 1019 ALL Tcell 5 5 I 0 0 I 9.5 4 12.5 3 720 ALL LR 2.5 9 I 0 0 I 10,9.5 9.5,12 9.5,12 10,8 12.5,8.521 ALL LR 2.5 7 I 0 0 I 6.5 2,5 7,8 3 622 ALL SR 5 15 III 0 0 I 10.5 5.5 22 5.5 1223 ALL SR 5 2 I 0 0 I 14 11 24 11.5 1924 ALL Tcell 5 5 I 0 0 I 11 3.5 12 4 825 ALL SR 5 13 I 0 0 I 16 11 24 11 1826 ALL LR 2.5 4 I 0 0 I 12 4 21.5 5 1627 ALL LR 2.5 5 I 0 0 I 5,21.5 9.5 16 7.5 1828 ALL LR 2.5 9 I 0 0 I 11.5 6 22.5 5 1329 All SR 5 13 II 0 0 I 7 4 9.5 3.5 7MTX: Methotrexate; CNS: Central Nervous System; C.N: Clinical Neurotoxicity; R.N: Radiological Neurotoxicity;NNR: Neurotoxicity Net Result
Figure 2: Homocysteine levels at initial (diagnosis) and during the consolidation phase HDMTX.*Significantly different from diagnosis (initial) value at P≤ 0.05, α significantly different from the correspondingpre administration value at P ≤ 0.05.
3.2 Methotrexate-induced neurotoxicityNeurotoxicity was assessed qualitatively as the aim wasto correlate it with the Hcy level. After HDMTXadministration, 17 (58%) patients had featuressuggestive of neurotoxicity with newly developedchanges in either MRI findings or clinical neurologicalexamination or both of them. Clinical neurologicalmanifestations were shown in 14 patients where it wasthe solitary finding in 12 patients and associated to MRIchanges in the remaining 2 patients. On the other hand
MRI changes were shown in 5 patients where it wasassociated to clinical neurological findings in 2 patientsand as a solitary finding in the remaining 3 patientsTable 3.
3.3 Correlation between Hcy levels and various
factorsA. Final positive Hcy: A highly significantcorrelation was found between final positive Hcyvalue (>15 µmol/L) whenever detected at leastonce in relation to HDMTX and the developmentof neurotoxicity (p = 0.05). The same was foundbetween final positive Hcy value and the HDMTX dose whether 5 g/m2 or 2.5 g/m2 (P =
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0.023). However, Hcy was positive if age ≤ 10years and CNS I or II, but not statisticallysignificant Table 4.A highly significant relation was found betweenfinal Hcy level and initial Hcy level as in 11 patients,the initial Hcy level was 9 µmol/L +/- 1.82 SD. Thiscorresponded to negative final Hcy level, while in 18
patients; the initial level was 14 µmol/L +/- 4.09 SD.This corresponded to positive final Hcy level p =0.001.B. Hcy at different checkpoints: A significantrelation between Hcy level post 1st HDMTX andHcy level post 2nd HDMTX as (p = 0.006) Table 5.
Table 4: Correlation between the final Hcy level and various prognostic factors.MTX Neurotoxicity p=0.05 Final Hcy valueNegative (5-15 µmol/L) Positive >15µmol/LNo neurotoxicity 9(31%) 5(17%)Presence of neurotoxicity 2(7%) 13(45%)MTX Dose p=0.0232.5 g/m2 6(21%) 3(10%)5 g/m2 5(17%) 15(52 %)Age p=0.41≤ 10 years> 10 years 9(31%)2(7%) 11(38%)7(24%)CNS Status p=0.281IIIIII 7(24%)2(7%)2(7%) 14 (48%)4 (14%)(0%)
Table 5: Correlation between Hcy levels post 2nd and 1st HDMTX.Hcy level post 2nd HDMTX
P=0.006 Hcy level post 1st HDMTXNegative PositiveNegative 11 patients (38%) 7(24%)Positive 1(3%) 10(34%)
3.4 Correlation between neurotoxicity and
various factorsNo significant relation was found between MTXneurotoxicity and various factors including age, MTXdose, patients CNS status and initial Hcy levels. Table 6
Table 6: Correlation between neurotoxicity and variousvariables. MTX neurotoxicityNegative PositiveAge (p=0.427)≤ 10 years> 10 11(38%)3(10%) 9 (31%)6 (21%)MTX Dose (p=0.7)2.5 g 5 (17%) 4 (14%)5 g 9 (31%) 11 (38%)CNS Status(p=0.092)IIIIII 11 (38%)1 (3%)2 (7%) 10(34%)5 (17%)0 (0%)Moreover, there was no correlation between MTXneurotoxicity and initial Hcy levels, as 14 patientsshowed a mean of 11 µmol/L +/- 3.69 SD correspondingto negative neurotoxicity oppositely to13 µmol/L +/-4.54 SD corresponding to positive neurotoxicity in 15patients.
4. DiscussionIn our study, we found a statistically significantcorrelation between higher plasma Hcy levels andhigher dose of MTX 5 g versus 2.5 g and patients withneurotoxicity either clinically or radiologically or both.Kishi et al. 2003, recorded a significant higher plasmaHcy levels among patients with seizures following HDMTX.26 The same as for an increased risk forencephalopathy after the administration of HD MTX andcoinciding with higher MTX level at hour 42 and a higherHcy concentration in the 1st HD MTX.27Hyperhomocysteinemia is classified as mild (15-30µmol/L), moderate (31-100 µmol/L) or severe (>100µmol/L).28 However, the correlation betweenneurotoxicity and higher level of Hcy was not provedafter the administration of MTX 1 or 3 gm/m2.29In the current study, Hcy levels post 1st HDMTX werehigher than their levels post 2nd HDMTX and both werehigher than their corresponding levels prior to HDMTX.These levels prior to HDMTX were however lesser thanthose at diagnosis. This goes with the higher baselineHcy level before therapy among our patients that mighthave probably reflected their disease burden andoccasional folate deficiency.8 However, such baselinedifferences between risk groups were shown by the endof a 6-week remission induction therapy in other
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studies.26 In the study of Kubota et al. 29 a significant riseof the mean Hcy levels at 24 hours was observed ascompared to those before HDMTX treatment, then at 48and 72 hours there were slight decreases in Hcy levelsbut these values were still significantly higher than theinitial levels.29In the current study more than half of the casesdeveloped neurotoxicity attributed to MTX. It includedmainly solitary clinical manifestations representing 4times the solitary radiological manifestations and 6times combined clinical and radiological ones. Theseresults might be due to over expression of clinicalmanifestations especially if confounded with GImanifestations of MTX toxicity. In other studies,neurotoxicity was observed after the administration ofHDMTX (2g/m2 or 5g/m2) to children with newlydiagnosed ALL.30-31 Bhojwani et al. collected data frompatients with ALL enrolled onto the total therapy XVstudy.27 They observed that 3.8% of the patientsdeveloped MTX-related subacute neurotoxic eventsduring the consolidation and the continuation phase.Most episodes were brief, but ataxia persisted for 4weeks. Moreover, Faganel et al. conducted a study onpatients diagnosed with ALL and T-cell lymphoma.Neurotoxicity was observed in 23% of the patients.32
5. ConclusionIn conclusion, the results of the present study showedthat plasma Hcy concentration was significantly elevatedafter HDMTX administration and this elevation is relatedto the observed neurotoxicity. Whether the elevation inHcy concentration can prove an informative biomarkerfor neurotoxicity requires additional testing withalternative regimens of MTX.
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